Shares of clinical-stage biopharmaceutical company Regulus Therapeutics (NASDAQ:RGLS) are flying higher today after it reported positive topline data from the Phase 1 trial of its candidate RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
In the Phase 1 single-ascending dose (SAD) study the drug was well tolerated in healthy volunteers. Now, Regulus has initiated a Phase 1b multiple ascending dose (MAD) study, and topline data from its first cohort is anticipated in the first half of 2023.
ADPKD is a leading cause of end-stage renal disease. About 160,000 people are diagnosed with ADPKD in the U.S. and its global prevalence is about 4 to 7 million.
Read full Disclosure
